Ossifix Orthopedics Debuts Demineralized Bone Matrix

Umbra Applied Technologies Group Inc. subsidiary Ossifix Orthopedics has launched a new demineralized bone matrix product.

Demineralized bone matrix (DBM) is often referred to as “crunch” and is made from human bone tissue. Ossifix Orthopedics DBM/Crunch contains no carrier or filler additives and is engineered to be resistant to washing away or migrating from surgical site. 
 
“Our newly launched crunch contains cancellous bone fragments within the crunch to provide the osteoconductive scaffolding to promote new bone growth,” Ossifix CEO Mark Estrada stated. “Healthcare practitioners can choose to add fresh marrow aspirate or allograft from the patient to promote further osteogenesis. We anticipate manufacturing to trail our newly launched Javelin cortical allograft bone pin with 12% to 20% growth month over which is in line with our estimation of 1,922 cases this year. This equates to about $1.1 million in additional or collateral sales over the next several months”.
 
Ossifix engineers and manufactures 100% allograft bone implants for small bone, extremities, and sports medicine markets with applications in the craniofacial, spine and oral surgery procedures. The resorbable implant technology can work synergistically in support of osteogenesis as both an osteoinductive and osteoconductive matrix. The DBM contains biologically active morphogenic proteins to promote mesenchymal cells differentiation into chondrocytes and osteoblasts. With these new proteins introduced to the surgical site, new bone formation will be promoted and accelerate healing.
 
Based in Austin, TX, Ossifix Orthopedics’ patent pending products are manufactured from select, allograft cortical bone. Ossifixs’ manufacturing process and patent pending designs yield advanced orthopedic products engineered to provide secure fixation while virtually eliminating any allergic or autoimmune reactions associated with metal or plastic/polymer products. 
 
The Ossifix Orthopedics product line will compete in one of the fastest growing, emerging markets, specifically, the resorbable implant market, in three distinct surgical segments; orthopedic, dental, and general. The demineralized bone matrix market is projected to reach $838.9 million by 2028, growing 4.3% annually.

Ossifix products are designed to be used in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe, Asia Pacific, as well as the Middle East and Africa. This global market is currently experiencing an estimated growth of 14% annually and is expected to reach $4.696 billion in sales this year. 
 
“The Ossifix team has continued to meet with health care facilities and professionals across orthopedic disciplines with significant response,” Umbra Applied Technologies Group CEO Alex Umbra said, “Ossifix is well positioned to expand their market share as they continue to develop and release their suite of products over the course of this year. I believe the Ossifix brand will be a regular staple within the global healthcare system.”

Located in Tampa, Fla., and focusing on advanced technologies across many disciplines, UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to its subsidiaries.